Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis.
Fagnani D, Franchi R, Porta C, Pugliese P, Borgonovo K, Bertolini A, Duro M, Ardizzoia A, Filipazzi V, Isa L, Vergani C, Milani M, Cimminiello C; POLONORD Group. Fagnani D, et al. Among authors: ardizzoia a. Ann Oncol. 2007 Mar;18(3):551-5. doi: 10.1093/annonc/mdl431. Epub 2006 Dec 8. Ann Oncol. 2007. PMID: 17158773 Free article. Clinical Trial.
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E; Italian Trials in Medical Oncology (ITMO) group. Procopio G, et al. Ann Oncol. 2013 Dec;24(12):2967-71. doi: 10.1093/annonc/mdt375. Epub 2013 Sep 24. Ann Oncol. 2013. PMID: 24063860 Free article. Clinical Trial.
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, Bonetti A, Campostrini F, Gardani G, Ardizzoia A, Dondi D, Guaraldi M, Cavallo R, Tomio L, Gava A; Gruppo di Studio Tumori della Testa e del Collo XRP 6976 F/2501 Study. Paccagnella A, et al. Among authors: ardizzoia a. Ann Oncol. 2010 Jul;21(7):1515-1522. doi: 10.1093/annonc/mdp573. Epub 2009 Dec 23. Ann Oncol. 2010. PMID: 20032123 Free article. Clinical Trial.
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
Barni S, Piazza E, Frontini L, Visini M, Ardizzoia A, Grassi MM, Nosenzo MA, Mandalà M, Biasioli R, Freddi E, Lucani L, Recalcati A, Pravettoni A, Sala R, Rezzani C, Villa S, Trabucchi E; Neo-Adjuvant Breast Italian Group. Barni S, et al. Among authors: ardizzoia a. Oncology. 2004;67(1):40-7. doi: 10.1159/000080284. Oncology. 2004. PMID: 15459494 Clinical Trial.
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study.
Cascinu S, Barni S, Labianca R, Del Ferro E, Rocchi MB, Ligi M, Pessi MA, Cazzaniga M, Zamparelli G, Ardizzoia A, Ugolini G, Ghiandoni G, Luporini G, Catalano G. Cascinu S, et al. Among authors: ardizzoia a. Support Care Cancer. 1997 Jul;5(4):314-7. doi: 10.1007/s005200050079. Support Care Cancer. 1997. PMID: 9257428 Clinical Trial.
151 results